Brokerages Expect Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Will Announce Quarterly Sales of $7.95 Million

Equities research analysts expect that Opiant Pharmaceuticals Inc (NASDAQ:OPNT) will report sales of $7.95 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Opiant Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $7.79 million and the highest estimate coming in at $8.10 million. Opiant Pharmaceuticals reported sales of $4.76 million in the same quarter last year, which would suggest a positive year over year growth rate of 67%. The company is expected to report its next quarterly earnings report on Thursday, March 19th.

On average, analysts expect that Opiant Pharmaceuticals will report full-year sales of $40.77 million for the current fiscal year, with estimates ranging from $40.64 million to $40.90 million. For the next year, analysts expect that the business will post sales of $29.93 million, with estimates ranging from $23.05 million to $36.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Opiant Pharmaceuticals.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Tuesday, November 12th. The technology company reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.87. The firm had revenue of $20.64 million for the quarter, compared to analysts’ expectations of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 7.39% and a net margin of 24.16%.

OPNT has been the subject of a number of recent research reports. TheStreet upgraded Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research note on Friday, August 30th. Northland Securities reaffirmed a “buy” rating and issued a $42.00 price target on shares of Opiant Pharmaceuticals in a research report on Thursday, November 7th.

In other news, Director Michael Sinclair sold 60,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $12.52, for a total transaction of $751,200.00. Also, insider Phil Skolnick sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $14.15, for a total transaction of $141,500.00. Following the sale, the insider now owns 10,000 shares in the company, valued at $141,500. The disclosure for this sale can be found here. Insiders sold a total of 90,000 shares of company stock valued at $1,197,500 over the last 90 days. 30.88% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of OPNT. Advisor Group Inc. lifted its position in shares of Opiant Pharmaceuticals by 24.3% in the second quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock valued at $61,000 after acquiring an additional 900 shares in the last quarter. BlackRock Inc. grew its position in shares of Opiant Pharmaceuticals by 93.5% during the second quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock worth $276,000 after purchasing an additional 10,045 shares in the last quarter. Morgan Stanley grew its position in shares of Opiant Pharmaceuticals by 1,000.3% during the second quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock worth $297,000 after purchasing an additional 20,377 shares in the last quarter. Wedge Capital Management L L P NC bought a new stake in Opiant Pharmaceuticals during the 3rd quarter valued at approximately $363,000. Finally, Stonepine Capital Management LLC raised its stake in Opiant Pharmaceuticals by 7.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock valued at $4,180,000 after purchasing an additional 20,574 shares during the period. Institutional investors and hedge funds own 21.49% of the company’s stock.

OPNT stock traded up $0.18 on Friday, reaching $14.18. 1,561 shares of the company traded hands, compared to its average volume of 23,917. Opiant Pharmaceuticals has a one year low of $9.98 and a one year high of $18.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.28 and a quick ratio of 4.28. The company has a market cap of $58.00 million, a P/E ratio of -2.00 and a beta of 0.25. The firm has a fifty day simple moving average of $14.76 and a 200-day simple moving average of $13.80.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

See Also: What are the benefits of a portfolio tracker?

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.